vs

Side-by-side financial comparison of NATIONAL RESEARCH CORP (NRC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $35.2M, roughly 1.1× NATIONAL RESEARCH CORP). On growth, NATIONAL RESEARCH CORP posted the faster year-over-year revenue change (-4.6% vs -57.1%). Over the past eight quarters, NATIONAL RESEARCH CORP's revenue compounded faster (-0.2% CAGR vs -46.5%).

National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

NRC vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$37.2M
$35.2M
NRC
Growing faster (revenue YoY)
NRC
NRC
+52.4% gap
NRC
-4.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
NRC
NRC
Annualised
NRC
-0.2%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NRC
NRC
ORGO
ORGO
Revenue
$35.2M
$37.2M
Net Profit
$1.8M
Gross Margin
30.8%
Operating Margin
13.3%
-185.1%
Net Margin
5.1%
Revenue YoY
-4.6%
-57.1%
Net Profit YoY
-72.6%
EPS (diluted)
$49.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NRC
NRC
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$35.2M
$225.6M
Q3 25
$34.6M
$150.9M
Q2 25
$34.0M
$101.0M
Q1 25
$33.6M
$86.7M
Q4 24
$36.9M
$126.7M
Q3 24
$35.8M
$115.2M
Q2 24
$35.0M
$130.2M
Net Profit
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
$1.8M
$43.7M
Q3 25
$4.1M
$21.6M
Q2 25
$-106.0K
$-9.4M
Q1 25
$5.8M
$-18.8M
Q4 24
$6.6M
$7.7M
Q3 24
$5.7M
$12.3M
Q2 24
$6.2M
$-17.0M
Gross Margin
NRC
NRC
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
NRC
NRC
ORGO
ORGO
Q1 26
-185.1%
Q4 25
13.3%
28.1%
Q3 25
22.4%
13.7%
Q2 25
4.7%
-12.5%
Q1 25
25.6%
-30.9%
Q4 24
26.0%
8.1%
Q3 24
22.3%
5.4%
Q2 24
25.3%
-10.7%
Net Margin
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
5.1%
19.4%
Q3 25
11.9%
14.3%
Q2 25
-0.3%
-9.3%
Q1 25
17.2%
-21.7%
Q4 24
17.8%
6.1%
Q3 24
15.9%
10.7%
Q2 24
17.6%
-13.1%
EPS (diluted)
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
$49.58
$0.31
Q3 25
$0.18
$0.11
Q2 25
$-0.01
$-0.10
Q1 25
$0.25
$-0.17
Q4 24
$0.27
$0.05
Q3 24
$0.24
$0.09
Q2 24
$0.26
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NRC
NRC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$4.1M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$14.0M
Total Assets
$134.9M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NRC
NRC
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$4.1M
$93.7M
Q3 25
$2.2M
$63.7M
Q2 25
$5.3M
$73.1M
Q1 25
$2.5M
$110.0M
Q4 24
$4.2M
$135.6M
Q3 24
$3.5M
$94.3M
Q2 24
$485.0K
$89.9M
Total Debt
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$48.7M
$62.3M
Q2 24
$33.3M
$63.8M
Stockholders' Equity
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
$14.0M
$300.1M
Q3 25
$14.3M
$255.1M
Q2 25
$21.3M
$233.2M
Q1 25
$29.7M
$242.9M
Q4 24
$31.3M
$262.9M
Q3 24
$34.6M
$278.5M
Q2 24
$40.2M
$263.5M
Total Assets
NRC
NRC
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$134.9M
$598.7M
Q3 25
$135.7M
$509.8M
Q2 25
$141.4M
$461.1M
Q1 25
$135.2M
$467.4M
Q4 24
$132.5M
$497.9M
Q3 24
$131.8M
$446.3M
Q2 24
$119.1M
$443.2M
Debt / Equity
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.41×
0.22×
Q2 24
0.83×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NRC
NRC
ORGO
ORGO
Operating Cash FlowLast quarter
$7.2M
Free Cash FlowOCF − Capex
$6.1M
FCF MarginFCF / Revenue
17.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
3.99×
TTM Free Cash FlowTrailing 4 quarters
$15.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
$7.2M
$39.4M
Q3 25
$13.8M
$3.1M
Q2 25
$-1.1M
$-32.9M
Q1 25
$6.6M
$-19.9M
Q4 24
$6.4M
$10.9M
Q3 24
$9.4M
$8.7M
Q2 24
$6.8M
$4.7M
Free Cash Flow
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
$6.1M
$34.8M
Q3 25
$10.2M
$844.0K
Q2 25
$-4.1M
$-36.5M
Q1 25
$3.7M
$-23.6M
Q4 24
$1.9M
$7.6M
Q3 24
$7.8M
$6.1M
Q2 24
$1.5M
$2.9M
FCF Margin
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
17.2%
15.4%
Q3 25
29.4%
0.6%
Q2 25
-12.2%
-36.1%
Q1 25
10.9%
-27.2%
Q4 24
5.2%
6.0%
Q3 24
21.8%
5.3%
Q2 24
4.3%
2.2%
Capex Intensity
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
3.2%
2.1%
Q3 25
10.4%
1.5%
Q2 25
8.8%
3.6%
Q1 25
8.9%
4.2%
Q4 24
12.0%
2.7%
Q3 24
4.5%
2.2%
Q2 24
15.0%
1.4%
Cash Conversion
NRC
NRC
ORGO
ORGO
Q1 26
Q4 25
3.99×
0.90×
Q3 25
3.34×
0.14×
Q2 25
Q1 25
1.15×
Q4 24
0.97×
1.43×
Q3 24
1.66×
0.71×
Q2 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons